Abstract: Disclosed is a novel peptide, which is a highly functional peptide derived from a natural fermentation product exhibiting an anti-wrinkle activity. A tetrapeptide consists of an amino acid sequence of glycine (Gly)-glutamine (Gln)-valine (Val)-serine (Ser) (SEQ ID NO: 1). The peptide is synthesized by utilizing 2-(4-nitrophenyl)sulfonylethoxycarbonyl-amino acid (Nsc-amino acid) as an intermediate. The anti-wrinkle activity is exhibited through the inhibition of elastase. The anti-wrinkle activity is exhibited through collagen synthesis.

Abstract: The present application provides an optical film. By controlling transmittance of a liquid crystal layer comprising a radical initiator for the maximum absorption wavelength of the radical initiator, the present application can provide an optical film having a liquid crystal layer having excellent resistance to external stimuli and excellent optical properties. Such an optical film can have various forms and can be used in various fields.

Abstract: An eye drop composition for treating glaucoma is disclosed. The eye drop composition includes a prostaglandin analogue, a thickening agent, and a solubilizing agent, wherein the thickening agent is carboxymethylcellulose or a salt thereof, and the solubilizing agent is tyloxapol.

Abstract: The present application provides an optical film. By controlling transmittance of a liquid crystal layer comprising a radical initiator for the maximum absorption wavelength of the radical initiator, the present application can provide an optical film having a liquid crystal layer having excellent resistance to external stimuli and excellent optical properties. Such an optical film can have various forms and can be used in various fields.

Abstract: The present invention relates to a process for preparing latanoprostene bunod and an intermediate therefor. In accordance with the preparation process of the present invention, latanoprostene bunod can be efficiently and cost-effectively prepared while reducing side reactions.

Abstract: The present invention relates to a cost-effective and efficient method for preparing treprostinil with high purity, and an intermediate therefor.

Abstract: The present invention relates to a process for preparing latanoprostene bunod and an intermediate therefor. In accordance with the preparation process of the present invention, latanoprostene bunod can be efficiently and cost-effectively prepared while reducing side reactions.

Abstract: An eye drop composition for treating glaucoma is disclosed. The eye drop composition includes a prostaglandin analogue, a thickening agent, and a solubilizing agent, wherein the thickening agent is carboxymethylcellulose or a salt thereof, and the solubilizing agent is tyloxapol.

Abstract: A method for preparing a 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivative by a simple process with high yields, and an intermediate useful for the method.

Abstract: A skin whitening method including: administering to a subject a cosmetic composition including a tranexamic acid-peptide having skin whitening activity selected from the group consisting of Tranexamil-AS, Tranexamil-AT, Tranexamil-AP, Tranexamil-GP, Tranexamil-ES, Tranexamil-KK, Tranexamil-HK, Tranexamil-MY, Tranexamil-GH, Tranexamil-MA, Tranexamil-AH, Tranexamil-CC, Tranexamil-SA, Tranexamil-WA, Tranexamil-WE, Tranexamil-KD, Tranexamil-NA, Tranexamil-TS, Tranexamil-SS, Tranexamil-EC, Tranexamil-TA, Tranexamil-PF, Tranexamil-VS, Tranexamil-VV, Tranexamil-VP, Tranexamil-AA, Tranexamil-PS, Tranexamil-HA, Tranexamil-GK, Tranexamil-KV, Tranexamil-AR, Tranexamil-RP, Tranexamil-PQ, Tranexamil-QG, Tranexamil-PP, Tranexamil-VR, Tranexamil-SV, Tranexamil-ET, Tranexamil-CG and Tranexamil-NT.

Abstract: A skin whitening method including: administering to a subject a cosmetic composition including a tranexamic acid-peptide having skin whitening activity selected from the group consisting of Tranexamil-AS, Tranexamil-AT, Tranexamil-AP, Tranexamil-GP, Tranexamil-ES, Tranexamil-KK, Tranexamil-HK, Tranexamil-MY, Tranexamil-GH, Tranexamil-MA, Tranexamil-AH, Tranexamil-CC, Tranexamil-SA, Tranexamil-WA, Tranexamil-WE, Tranexamil-KD, Tranexamil-NA, Tranexamil-TS, Tranexamil-SS, Tranexamil-EC, Tranexamil-TA, Tranexamil-PF, Tranexamil-VS, Tranexamil-VV, Tranexamil-VP, Tranexamil-AA, Tranexamil-PS, Tranexamil-HA, Tranexamil-GK, Tranexamil-KV, Tranexamil-AR, Tranexamil-RP, Tranexamil-PQ, Tranexamil-QG, Tranexamil-PP, Tranexamil-VR, Tranexamil-SV, Tranexamil-ET, Tranexamil-CG and Tranexamil-NT.

Abstract: The present invention relates to a cost-effective and efficient method for preparing treprostinil with high purity, and an intermediate therefor.

Abstract: A method for preparing a 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivative by a simple process with high yields, and an intermediate useful for the method.

Abstract: The disclosure is related to grouping and displaying messages exchanging between a sender and a plurality of recipients. A first message including a first tag may be sent to a plurality of recipient terminals. A second message may be received from at least one of the recipient terminals. The received second message may be grouped into a related message group based on the first tag and a second tag. The second tag may be included in the second message. The received second messages may be displayed within the related message group.

Abstract: The present invention relates to a process for preparing a prostaglandin derivative and an intermediate therefor. In accordance with the present invention, the prostaglandin F (PGF) derivative can be efficiently prepared with high purity by removing the protecting group of a protected prostaglandin E (PGE) derivative obtained from conjugate addition and then stereoselectively reducing the ketone group on the cyclopentanone ring of the PGE derivative.

Abstract: The present invention relates to a process for preparing a prostaglandin derivative and an intermediate therefor. In accordance with the present invention, the prostaglandin F (PGF) derivative can be efficiently prepared with high purity by removing the protecting group of a protected prostaglandin E (PGE) derivative obtained from conjugate addition and then stereoselectively reducing the ketone group on the cyclopentanone ring of the PGE derivative.

Abstract: The present invention relates to a process for preparing a prostaglandin derivative and an intermediate therefor. In accordance with the present invention, the prostaglandin F (PGF) derivative can be efficiently prepared with high purity by removing the protecting group of a protected prostaglandin E (PGE) derivative obtained from conjugate addition and then stereoselectively reducing the ketone group on the cyclopentanone ring of the PGE derivative.

Abstract: The present invention relates to a process for effectively preparing prostaglanin derivatives and to a stereospecific alkyl halide containing 15S-alcohol group as a starting material.

Abstract: The present invention relates to a process for effectively preparing prostaglanin derivatives and to a stereospecific alkyl halide containing 15S-alcohol group as a starting material.

Abstract: The present invention relates to a novel process for preparing sulfamoyl-substituted phenethylamine derivatives, specifically, 5-{2-[2-(2-alkoxy-phenoxy)ethylamino]-propyl}-2-methoxy-benzene sulfonamide of the formula (1).